$TESI
Titan Environmental Solutions Inc Stock $tesi

$tesi Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224014667 Filed on April 15, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$1.756M	$2.056M	$7.625M
YoY Change	2599.49%	130049.37%	481858.53%
Cost Of Revenue	$1.623M	$1.799M	$6.503M
YoY Change	4261.45%	3219.22%	11896.41%
Gross Profit	$132.6K	$257.0K	$1.121M
YoY Change	376.55%	-588.33%	-2230.94%
Gross Profit Margin	7.55%	12.5%	14.71%
Selling, General & Admin	$1.762M	$1.949M	$11.53M
YoY Change	459.05%	49.18%	782.48%
% of Gross Profit	1328.95%	758.52%	1028.34%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$192.9K	$147.9K	$505.4K
YoY Change	-52.93%	546.7%	1420.56%
% of Gross Profit	145.46%	57.55%	45.07%
Operating Expenses	$1.955M	$1.780M	$32.40M
YoY Change	169.66%	32.83%	2317.96%
Operating Profit	-$1.822M	-$1.523M	-$31.28M
YoY Change	161.4%	9.36%	2146.06%
Interest Expense	-$493.0K	-$695.0K	-$1.338M
YoY Change	-99.56%	-74.84%	-51.54%
% of Operating Profit
Other Income/Expense, Net	-$436.6K	-$28.26K	-$117.7M
YoY Change	-99.61%		11565.48%
Pretax Income	-$2.259M	-$6.849M	-$149.0M
YoY Change	-97.98%	185.16%	6103.78%
Income Tax
% Of Pretax Income
Net Earnings	-$2.259M	-$7.924M	-$149.0M
YoY Change	-97.98%	-13.6%	1524.64%
Net Earnings / Revenue	-128.66%	-385.35%	-1954.27%
Basic Earnings Per Share	-$0.01		-$0.88
Diluted Earnings Per Share	-$0.01	-$0.52	-$0.88
COMMON SHARES
Basic Shares Outstanding	25.39M shares	15.13M shares	170.7M shares
Diluted Shares Outstanding	222.1M shares		170.7M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.430K	$103.6K	$103.6K
YoY Change	-97.54%	7806.87%	7806.87%
Cash & Equivalents	$3.427K	$103.6K
Short-Term Investments
Other Short-Term Assets	$219.0K	$248.9K	$248.9K
YoY Change	1885.13%	447.89%	282.09%
Inventory	$219.9K	$145.0K	$145.0K
Prepaid Expenses
Receivables	$934.9K	$970.6K	$970.6K
Other Receivables	$0.00	$7.350K	$7.350K
Total Short-Term Assets	$1.377M	$1.475M	$1.475M
YoY Change	138.96%	2120.12%	2120.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.403M	$5.781M	$7.363M
YoY Change	553778.63%
Goodwill	$6.517M	$6.517M
YoY Change	-10.64%
Intangibles	$6.462M	$6.654M
YoY Change	-38.14%
Long-Term Investments
YoY Change
Other Assets	$668.2K	$165.7K	$165.7K
YoY Change
Total Long-Term Assets	$21.53M	$20.70M	$20.70M
YoY Change	21.36%
TOTAL ASSETS
Total Short-Term Assets	$1.377M	$1.475M	$1.475M
Total Long-Term Assets	$21.53M	$20.70M	$20.70M
Total Assets	$22.91M	$22.18M	$22.18M
YoY Change	25.06%	33266.65%	33266.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.364M	$3.476M	$3.476M
YoY Change	368.04%	1436.64%	1436.64%
Accrued Expenses	$1.258M	$979.5K	$979.5K
YoY Change	959.48%	3944.3%	3944.3%
Deferred Revenue
YoY Change
Short-Term Debt	$2.984M	$2.872M	$2.872M
YoY Change
Long-Term Debt Due	$4.420M	$3.911M	$4.636M
YoY Change	22.51%	420.22%	281.33%
Total Short-Term Liabilities	$14.50M	$12.41M	$12.41M
YoY Change	-87.66%	637.56%	637.56%
LONG-TERM LIABILITIES
Long-Term Debt	$3.281M	$3.175M	$3.175M
YoY Change
Other Long-Term Liabilities	$1.200M	$1.291M	$1.291M
YoY Change
Total Long-Term Liabilities	$4.717M	$4.466M	$4.466M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.50M	$12.41M	$12.41M
Total Long-Term Liabilities	$4.717M	$4.466M	$4.466M
Total Liabilities	$19.22M	$16.88M	$16.88M
YoY Change	-83.64%	902.95%	902.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$153.2M	-$150.1M
YoY Change	18.41%	756.49%
Common Stock	$2.539K	$1.513K
YoY Change	-25.19%	-16.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.690M	$5.299M	$5.299M
YoY Change
Total Liabilities & Shareholders Equity	$22.91M	$22.18M	$22.18M
YoY Change	25.06%	33266.65%	33266.64%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$2.259M	-$7.924M	-$149.0M
YoY Change	-97.98%	-13.6%	1524.64%
Depreciation, Depletion And Amortization	$192.9K	$147.9K	$505.4K
YoY Change	-52.93%	546.7%	1420.56%
Cash From Operating Activities	-$822.5K	-$1.095M	-$3.249M
YoY Change	327.38%	162.71%	121.76%
INVESTING ACTIVITIES
Capital Expenditures	$734.9K	$483.8K	$657.4K
YoY Change		151093.75%	1876.86%
Acquisitions			-$69.10K
YoY Change
Other Investing Activities		$0.00	$166.4K
YoY Change
Cash From Investing Activities	-$734.9K	-$483.8K	-$491.0K
YoY Change	389.95%	151093.75%	1376.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.457M	1.084M	$3.817M
YoY Change	203.15%	332.06%	187.18%
NET CHANGE
Cash From Operating Activities	-$822.5K	-1.095M	-$3.249M
Cash From Investing Activities	-$734.9K	-483.8K	-$491.0K
Cash From Financing Activities	$1.457M	1.084M	$3.817M
Net Change In Cash	-$100.2K	-494.8K	$76.93K
YoY Change	-172.44%	197.63%	-145.46%
FREE CASH FLOW
Cash From Operating Activities	-$822.5K	-$1.095M	-$3.249M
Capital Expenditures	$734.9K	$483.8K	$657.4K
Free Cash Flow	-$1.557M	-$1.579M	-$3.906M
YoY Change	709.27%	278.49%	160.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	TESI	Subscription Receivable SubscriptionReceivable		usd
CY2022Q4	us-gaap	Inventory Net InventoryNet		usd
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	TESI	Customer Deposits CustomerDeposits		usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2022Q4	TESI	Shares To Be Issued Current SharesToBeIssuedCurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Members Capital MembersCapital		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit		usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization		usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022	TESI	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability		usd
CY2022	TESI	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable		usd
CY2023	TESI	Gain On Forgiveness Of Ppp Loans GainOnForgivenessOfPPPLoans		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2023	us-gaap	Stock Granted During Period Value Sharebased Compensation Forfeited StockGrantedDuringPeriodValueSharebasedCompensationForfeited		usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022	TESI	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable		usd
CY2023	TESI	Gain On Forgiveness Of Ppp Loans GainOnForgivenessOfPPPLoans		usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense		usd
CY2022	TESI	Change In Fair Value Of Derivative Liability And Derivative Expense ChangeInFairValueOfDerivativeLiabilityAndDerivativeExpense		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets		usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
CY2022	TESI	Increase Decrease In Deposit IncreaseDecreaseInDeposit		usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2022	TESI	Proceeds From Subscription Receivable ProceedsFromSubscriptionReceivable		usd
CY2023	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit		usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2022	TESI	Proceeds From Offering Fees On Issuance Of Warrants ProceedsFromOfferingFeesOnIssuanceOfWarrants		usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
CY2022	TESI	Repayments Of Note Payables Related Parties RepaymentsOfNotePayablesRelatedParties		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	TESI	Noncash Transactions Related To Reverse Acquisition NoncashTransactionsRelatedToReverseAcquisition		usd
CY2022	TESI	Settlement Of Note Payable SettlementOfNotePayable		usd
CY2023	us-gaap	Line Of Credit Assumed1 LineOfCreditAssumed1		usd
CY2023	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	TESI	Member Contributions In Exchange For Intangible Asset Purchase MemberContributionsInExchangeForIntangibleAssetPurchase		usd
CY2023Q4	TESI	Subscription Receivable SubscriptionReceivable		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2022Q4	TESI	Advance On Offering Current AdvanceOnOfferingCurrent		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber		shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber		shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023Q4	TESI	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedOutstandingNumber		shares
CY2023Q4	TESI	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedOutstandingWeightedAverageGrantDateFairValue
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount		shares
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	12808304	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25386814	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	317
CY2023	dei	Auditor Name AuditorName	Freed Maxick CPAs, P.C
CY2023	dei	Auditor Location AuditorLocation	Buffalo, New York
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103578	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26650	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	970629	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	517583	usd
CY2022Q4	TESI	Subscription Receivable SubscriptionReceivable	200000	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	7351	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	1241	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	248932	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	128689	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	145000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1475490	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	874163	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5780747	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5643941	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6654030	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	687500	usd
CY2023Q4	us-gaap	Goodwill Goodwill	6516915	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	165668	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8251	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1582624	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	194112	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	20699984	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	6533804	usd
CY2023Q4	us-gaap	Assets Assets	22175474	usd
CY2022Q4	us-gaap	Assets Assets	7407967	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4072958	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	736658	usd
CY2023Q4	TESI	Customer Deposits CustomerDeposits	226671	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	144326	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	50983	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	17500	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	391547	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	95243	usd
CY2023Q4	TESI	Shares To Be Issued Current SharesToBeIssuedCurrent	50000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12410598	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1981042	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1290866	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4465551	usd
CY2023Q4	us-gaap	Liabilities Liabilities	16876149	usd
CY2022Q4	us-gaap	Members Capital MembersCapital	2526104	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	0	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1513	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	155377798	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-150080049	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	5299325	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2526104	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22175474	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7407967	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7624584	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4203112	usd
CY2023	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1720492	usd
CY2022	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	475512	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	5590486	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	3146692	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	265575	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	505434	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1074634	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	359175	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	20364001	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	32401739	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	1100262	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-31280290	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1105002	usd
CY2023	TESI	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	41670	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	1380122	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	199453	usd
CY2023	TESI	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable	-91803	usd
CY2022	TESI	Gain On Forgiveness Of Ppp Loans GainOnForgivenessOfPPPLoans	-812305	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	113212	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-166513	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-116591322	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-117724759	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	446339	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-149005049	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-658663	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1075000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-150080049	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-658663	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.88
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.88
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	170715695	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	170715695	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2526104	usd
CY2023	TESI	Stock Issued During Period Value Settlement Of Note Due To Contribution StockIssuedDuringPeriodValueSettlementOfNoteDueToContribution	170000	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	27395569	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5590485	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	300000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	118322216	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	5299325	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2038379	usd
CY2022	TESI	Stock Issued During Period Value Member Contribution StockIssuedDuringPeriodValueMemberContribution	5223146	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-658663	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2526104	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-149005049	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-658663	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	20364001	usd
CY2023	TESI	Gain On Forgiveness Of Note Payable GainOnForgivenessOfNotePayable	-91803	usd
CY2022	TESI	Gain On Forgiveness Of Ppp Loans GainOnForgivenessOfPPPLoans	-812305	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-17965	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	77690	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	929454	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	325382	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5590486	usd
CY2023	TESI	Change In Fair Value Of Derivative Liability And Derivative Expense ChangeInFairValueOfDerivativeLiabilityAndDerivativeExpense	41670	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	403328	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	6663	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-116591322	usd
CY2022	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	-168208	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	65743	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	181549	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	102429	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	40374	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	6110	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-424775	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	80106	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	157417	usd
CY2023	TESI	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	-23339	usd
CY2022	TESI	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	-82258	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2370309	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	363010	usd
CY2023	TESI	Increase Decrease In Deposit IncreaseDecreaseInDeposit	-84873	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	72266	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	17944	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	60029	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-85303	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3248631	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-312264	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-69104	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	657445	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3349628	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	97319	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	371819	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-491022	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2977809	usd
CY2023	TESI	Proceeds From Subscription Receivable ProceedsFromSubscriptionReceivable	200000	usd
CY2022	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	99950	usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	267000	usd
CY2023	TESI	Proceeds From Offering Fees On Issuance Of Warrants ProceedsFromOfferingFeesOnIssuanceOfWarrants	33000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2595000	usd
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	114010	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	675000	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	870993	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	4398833	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1843871	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1015739	usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	1293419	usd
CY2023	TESI	Repayments Of Note Payables Related Parties RepaymentsOfNotePayablesRelatedParties	-159950	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3816581	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3283144	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	76928	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6929	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26650	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	33579	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	103578	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26650	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	578396	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	219404	usd
CY2023	TESI	Noncash Transactions Related To Reverse Acquisition NoncashTransactionsRelatedToReverseAcquisition	27162222	usd
CY2023	TESI	Settlement Of Note Payable SettlementOfNotePayable	170000	usd
CY2022	us-gaap	Line Of Credit Assumed1 LineOfCreditAssumed1	4505646	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	200000	usd
CY2022	TESI	Member Contributions In Exchange For Intangible Asset Purchase MemberContributionsInExchangeForIntangibleAssetPurchase	517500	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_805_eus-gaap--NatureOfOperations_zr9QnXiAYQe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_827_zmd8nvx028j4">ORGANIZATION AND NATURE OF OPERATIONS</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Titan Environmental Solutions Inc., formerly known as TraQiQ, Inc., (“Titan” or along with its wholly owned subsidiaries, referred to herein as the “Company”) is engaged in the full-service solution of waste management. As a result of a Merger Agreement with a wholly-owned subsidiary, the Company (at the time, TraQiQ, Inc., a California corporation) merged with and into Titan Environmental Solutions Inc., a Nevada corporation (the “reincorporation”). Titan was the surviving entity of the reincorporation which was effective January 10, 2024. Please see Note 20 – Subsequent Events for more information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is based out of Bloomfield Hills, Michigan and offers a comprehensive package of waste reduction, collection, recycling, and technology-enabled solutions to support customer demand. The Company operates two distinct lines of business. The Company’s wholly-owned subsidiary, Titan Trucking, LLC (“Titan Trucking”), is a non-hazardous solid waste management company providing waste and recycling collection and transportation services for industrial generators, commercial contractors and transfer station operators in Michigan. Titan Trucking maintains a fleet of roll off and tractor trailer trucks to perform its services. The Company’s wholly-owned subsidiary Recoup Technologies, Inc. (“Recoup”), provides technology-enabled solutions for food waste processing, including onsite digestors for food waste along with cloud-based software tracking and analytics solutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 19, 2023, the Company completed its acquisition of Titan Trucking and Titan Trucking’s wholly owned subsidiary, Senior Trucking, LLC (“Senior”). In accordance with ASC 805 - <i>Business Combinations </i>(“ASC 805”), the transaction was treated as a reverse acquisition for financial reporting purposes, with Titan treated as the legal acquirer and Titan Trucking treated as the accounting acquirer. Titan remains the continuing registrant and reporting company. Accordingly, the historical financial and operating data of the Company, which covers periods prior to the closing date of the Titan Merger, reflects the assets, liabilities, and results of operations for Titan Trucking and does not reflect the assets, liabilities and results of operations of Titan for the periods prior to May 19, 2023 (Note 3 – Business Combinations).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 28, 2023, the Company, its wholly owned subsidiary TraQiQ Solutions, Inc (“Ci2i”), and Ajay Sikka (“Sikka”), a director of the Company and its former chief executive officer, signed an Assignment of Stock Agreement (the “Assignment Agreement”). Under the terms of the Assignment Agreement, the Company assigned and transferred to Sikka all of the rights, title, and interests in the issued and outstanding equity interests of Ci2i in exchange for consideration of $<span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferred1_c20230728__20230728__srt--OwnershipAxis__custom--TraqiqSolutionsIncMember_zqdCrueN8zSa" title="Consideration exchange">1</span>. The Company additionally assumed from Ci2i loans and short term debts valued at $<span id="xdx_90C_eus-gaap--ShortTermBorrowings_iI_c20230728__srt--OwnershipAxis__custom--TraqiqSolutionsIncMember_zN7faWSiPHKa" title="Short term debt">209,587</span> plus fees and interest. Other than the liabilities assumed from Ci2i, the balance sheet amounts and operations of Ci2i as of the date of sale were insignificant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>March 31, 2023 Consolidated Financial Statements</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the preparation of the Company’s condensed consolidated financial statements reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, (collectively, “the second quarter financial statements”), the Company identified errors in its previously-issued condensed consolidated financial statements as of and for the period ended March 31, 2023. Management determined that these condensed consolidated financial statements incorrectly accounted for the January 5, 2023, acquisition of the Recoup digester business assets as a business combination instead of as an asset acquisition under the guidance enumerated in FASB ASC 805. The result of the change was to remove goodwill previously recorded ($<span id="xdx_909_eus-gaap--Goodwill_iI_pn5n6_c20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z9024Gnbsh1g" title="Goodwill">7.2</span> million) as part of the transaction and allocate that value to the intellectual property intangible asset. The Company also determined that the Black-Scholes model used to previously value the derivative liability was not appropriate and subsequently utilized a Monte Carlo pricing model, to more appropriately reflect the variability in the derivative. This resulted in a $<span id="xdx_906_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn5n6_c20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zoXRBzGmp758" title="Goodwill">112</span> million reduction of the derivative liability at March 31, 2023. The Company’s management and the Company’s Board of Directors concluded that due to the correction of the errors that were discovered, the previously issued unaudited condensed consolidated financial statements and other financial information contained in the Company’s Quarterly Reports on Forms 10-Q for the fiscal period ended March 31, 2023 should no longer be relied upon.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s acquisition of Titan Trucking on May 19, 2023 (Note 3 – Business Combinations) (the “Titan Merger”) was treated as a reverse acquisition under ASC 805 for financial reporting purposes, with Titan as the legal acquirer and Titan Trucking as the accounting acquirer. Titan Trucking’s historical consolidated financial statements have replaced Titan’s historical consolidated financial statements with respect to periods prior to the completion of the Titan Merger. Therefore, management believes the accounting errors identified do not impact the historical consolidated financial statements presented herein.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements as of December 31, 2023 and December 31, 2022 are prepared using accounting principles generally accepted in the United States of America (“GAAP”), which contemplates continuation of the Company as a going concern. This contemplates the realization of assets and liquidation of liabilities in the ordinary course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2023, the Company had a net loss of $<span id="xdx_907_eus-gaap--NetIncomeLoss_iN_di_c20230101__20231231_zN3J3aDS5SJc" title="Net income loss">149,005,049</span>. The working capital of the Company was a deficit of $<span id="xdx_908_ecustom--WorkingCapitalDeficit_iI_c20231231_zDKiXXiN6Btg" title="Working capital deficit">10,935,108</span> as of December 31, 2023 (deficit of $<span id="xdx_909_ecustom--WorkingCapitalDeficit_iI_c20221231_zgs0QwpguRM3" title="Working capital deficit">1,106,879</span> as of December 31, 2022). The December 31, 2023 working capital deficiency includes $<span id="xdx_90B_eus-gaap--RepaymentsOfDebt_c20230101__20231231_zYl2DROnMOr9" title="Principal repayment of note">2,307,090</span> of principal repayments from the Michaelson Note due by June 30, 2024; the Company currently does not have sufficient funds to repay this debt. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of time within one year after that date that the consolidated financial statements are issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management’s plans include raising capital through issuances of equity and debt securities, and minimizing operating expenses of the business to improve the Company’s cash burn rate. On July 17, 2023, the Company converted $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20230717_zG4UVPu3EFdl" title="Debt instrument face amount">1,944,000</span> of principal and $<span id="xdx_909_eus-gaap--InterestExpense_c20230717__20230717__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z1Zun452qbAf" title="Accrued interest">75,263</span> of accrued interest related to its outstanding convertible note payables into Series A rights to receive common stock (“Series A Rights”), resulting in the extinguishment of almost all of the Company’s convertible note embedded derivative liabilities. In addition, the Company has been successful in attracting substantial capital from investors interested in the current public status of the Company that has been used to support its ongoing cash outlays. This includes $<span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_c20231231_zvuouKeYWsgk" title="Convertible notes payable">2,595,000</span> of convertible notes during the year ended December 31, 2023 (Note 10 - Convertible Notes Payable). The Company believes, but cannot guarantee, it will continue to be able to attract capital from outside sources as it pursues a move to a national stock exchange. The Company has engaged a qualified investment bank to assist in the uplisting of its common stock and simultaneous raise of capital. In addition, the Company’s revenue continues to grow and management expects the Company to shrink its net losses over the upcoming quarters through organic and acquisitive growth. The Company has identified a plan to decrease expenses going forward to reduce its cash burn.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of these factors, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date the consolidated financial statements are issued. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-149005049	usd
CY2023Q4	TESI	Working Capital Deficit WorkingCapitalDeficit	10935108	usd
CY2022Q4	TESI	Working Capital Deficit WorkingCapitalDeficit	1106879	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	2307090	usd
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1944000	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2595000	usd
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	43016	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	77690	usd
CY2022Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	413723	usd
CY2022Q4	TESI	Subscription Receivable SubscriptionReceivable	200000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	20364001	usd
CY2023	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	385002	usd
CY2022	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	6663	usd
CY2023Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	434542	usd
CY2022Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	93745	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zeAGU4bJWcdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zYrPxXfnTfc2">Concentration Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company performs a regular review of customer activity and associated credit risks.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, four customers accounted for approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FourCustomerAMember_zK2EnJUgUZ91" title="Concentration risk, percentage">47</span>% of accounts receivable. As of December 31, 2022, one customer accounted for approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--OneCustomerAMember_z7QeSsZ4kz89" title="Concentration risk, percentage">63</span>% of accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, one customer accounted for approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--OneCustomerAMember_zjZEfOa6tqKk" title="Concentration risk, percentage">30</span>% of total revenues generated. During the year ended December 31, 2022, two customers accounted for approximately <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoCustomerAMember_z8NcMVtTozc4" title="Concentration risk, percentage">52</span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoCustomerBMember_z6cfYJ3bkUc7" title="Concentration risk, percentage">12</span>%, respectively, of total revenues generated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains positive customer relationships and continually expands its customer base, mitigating the impact of any potential concentration risks that exist.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	298917	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1682413	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	391547	usd
CY2023	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	The Company’s taxes are subject to examination by taxation authorities for a period of three years
CY2023	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	61724	usd
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	11336	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1290866	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	372162	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	112753	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1396000	usd
	us-gaap	Gross Profit GrossProfit	799.00	usd
CY2022	TESI	Share Based Compensation Pro Forma ShareBasedCompensationProForma	5590485	usd
CY2022	TESI	Goodwill Impairment Loss Pro Forma GoodwillImpairmentLossProForma	20364001	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7236057	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6741605	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1455310	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1097664	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5780747	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5643941	usd
CY2023	us-gaap	Depreciation Depreciation	424363	usd
CY2022	us-gaap	Depreciation Depreciation	325382	usd
CY2023Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	3932831	usd
CY2023Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	3228010	usd
CY2022Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	1118605	usd
CY2022Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	2858828	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	21385	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	53325	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	20447	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	73297	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	3911446	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	3174685	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	1098158	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	2785531	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	505091	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6654030	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	687500	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6654030	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	687500	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	505091	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	772466	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	770356	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	770356	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	770356	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	711930	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2858566	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6654030	usd
CY2023Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	3475570	usd
CY2022Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	669231	usd
CY2023Q4	TESI	Credit Card Payable CreditCardPayable	153728	usd
CY2022Q4	TESI	Credit Card Payable CreditCardPayable	29454	usd
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	233611	usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	12298	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	210049	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	25675	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	4072958	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	736658	usd
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M9D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y29D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0810	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0757	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	514193	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	460980	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	485504	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	418442	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	102211	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1981330	usd
CY2023Q4	TESI	Notes Payable Including Related Party Current NotesPayableIncludingRelatedPartyCurrent	3381446	usd
CY2023Q4	TESI	Notes Payable Including Related Party Non Current NotesPayableIncludingRelatedPartyNonCurrent	2571215	usd
CY2022Q4	TESI	Notes Payable Including Related Party Current NotesPayableIncludingRelatedPartyCurrent	1098158	usd
CY2022Q4	TESI	Notes Payable Including Related Party Non Current NotesPayableIncludingRelatedPartyNonCurrent	2785531	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	593383	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	183567	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	17500	usd
CY2023	TESI	Warrants Conversion Option Derivative Liabilities Recognized Due To Reverse Acquisition WarrantsConversionOptionDerivativeLiabilitiesRecognizedDueToReverseAcquisition	219172	usd
CY2023	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	160002	usd
CY2023	TESI	Derivative Gain Loss On Derivative DerivativeGainLossOnDerivative	-41670	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	17500	usd
CY2023Q4	TESI	Advance On Offering Current AdvanceOnOfferingCurrent	50000	usd
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	22500	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	20500	usd
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.50	pure
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	1	pure
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	15116	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	11164	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	TESI	Member Equity MemberEquity	2526104	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15134545	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15134545	shares
CY2023	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	300000	shares
CY2023Q3	TESI	Unreimbursed Advances UnreimbursedAdvances	100000	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1075000	usd
CY2023Q3	TESI	Unreimbursed Advances UnreimbursedAdvances	100000	usd
CY2023	TESI	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Unreleased In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnreleasedInPeriod	1405000	shares
CY2023	TESI	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Vested And Unreleased In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueVestedAndUnreleasedInPeriod	0.01
CY2023	TESI	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Unvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber	3600000	shares
CY2023	TESI	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Unvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueUnvestedNumber	0.01
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	300000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.01
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	4705000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.01
CY2023Q2	TESI	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Unreleasef In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnreleasefInPeriod	2005000	shares
CY2023Q3	TESI	Stock Issued During Period Shares Restricted Stock Award Vested Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardVestedForfeited	1705000	shares
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0034	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0000	pure
CY2023Q3	TESI	Stock Issued During Period Shares Restricted Stock Award Unvested Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardUnvestedForfeited	3000000	shares
CY2023Q4	TESI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Unreleased In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndUnreleasedInPeriodFairValue	16439	usd
CY2023	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	159600	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	99750	usd
CY2023Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	324000	usd
CY2023Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	324000	usd
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	65698734	shares
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-674213	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-265698	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-939911	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	939911	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.0000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0045	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0.0010	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0.0000	pure
CY2023	TESI	Effective Income Tax Rate Reconciliation Loss On Extinguishment Of Debt EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt	-0.1644	pure
CY2022	TESI	Effective Income Tax Rate Reconciliation Loss On Extinguishment Of Debt EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt	0.0000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.0235	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0.0000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.0079	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.0000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0063	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	14875000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	14900000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	1300000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	13600000	usd
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	limited in utilization of 80% of taxable income.
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4497000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7624584	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4203112	usd
CY2023	us-gaap	Gross Profit GrossProfit	1121449	usd
CY2022	us-gaap	Gross Profit GrossProfit	-4740	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-149005049	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-658663	usd
CY2023Q4	us-gaap	Assets Assets	22175474	usd
CY2022Q4	us-gaap	Assets Assets	7407967	usd
CY2023	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	657445	usd
CY2022	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	3349628	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	929454	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	325382	usd

Files In Submission

Name	View Source	Status
0001493152-24-014667-index-headers.html	Edgar Link	pending
0001493152-24-014667-index.html	Edgar Link	pending
0001493152-24-014667.txt	Edgar Link	pending
0001493152-24-014667-xbrl.zip	Edgar Link	pending
ex10-11.htm	Edgar Link	pending
ex10-12.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
ex4-5.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tesi-20231231.xsd	Edgar Link	pending
tesi-20231231_lab.xml	Edgar Link	unprocessable
tesi-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
tesi-20231231_cal.xml	Edgar Link	unprocessable
tesi-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TESI
Titan Environmental Solutions Inc Stock $tesi

2024 Q1 Form 10-K Financial Statement

#000149315224014667 Filed on April 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TESI Titan Environmental Solutions Inc Stock $tesi

2024 Q1 Form 10-K Financial Statement

#000149315224014667 Filed on April 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TESI
Titan Environmental Solutions Inc Stock $tesi